TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06387069
Drug: Salvage Chemotherapy Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition:~* MEC regimen: etoposide injection 100 mg/m2, cytarabine injection 1000 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).~* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4).~* LoDAC: cytarabine injection 20 mg q12h SC or IV for 10 consecutive days (Days 1-10).~* Azacitidine: azacitidine injection 75 mg/m2 QD SC or IV for 7 consecutive days (Days 1-7).
Study: NCT04335968
Drug: Melatonin 4 mg
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery.
Study: NCT04335968
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo of this drug with the same schedule, during the same period of time.
Study: NCT05899907
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
Study: NCT05434494
Drug: remifantanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
Study: NCT04728646
Drug: DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
Study: NCT04884763
Drug: Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (EREN-P) s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
Study: NCT05590520
Drug: GTN OINTMENT
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2%GTN applied on anal canal.
Study: NCT05934110
Drug: EMP16-120/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMP16 is supplied as oral MR capsules with the strength of 60 mg orlistat/20 mg acarbose.~Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose (2 capsules TID).
Study: NCT05934110
Drug: EMP16-60/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose plus placebo (1 capsule of each TID)
Study: NCT05934110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)
Study: NCT04762836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control in oral form
Study: NCT04884880
Drug: Luo-Fu-Shan Plaster
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luo-Fu-Shan Plaster 10g，once daily，4 weeks
Study: NCT04884880
Drug: The placebo 10g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10g，once daily，4 weeks
Study: NCT05322330
Drug: Flu
Normalized name: Fluex
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-30 mg/m2，d-5 ～d-3，qd，ivgtt
Study: NCT05322330
Drug: CTX
Normalized name: CTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-500 mg/m2，d-5 ～d-3，qd，ivgtt
Study: NCT05750355
Drug: TPN171H 10 mg Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.
Study: NCT05750355
Drug: TPN171H 30 mg Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.
Study: NCT05750355
Drug: TPN171H 40 mg Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.
Study: NCT05750355
Drug: TPN171H 50 mg Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.
Study: NCT04886986
Drug: 177Lu-PSMA-I&T
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.8 GBq (fixed dose) every 8 weeks, for up to 2 cycles. Administered together with 225Ac-J591. Intravenous administration.
Study: NCT05156879
Drug: Drospirenone ethinyl estradiol
Normalized name: drospirenone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 table/day, 21 consecutive days, 28 days as a cycle of use
Study: NCT06133192
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: steroids 2 mg/kg/d
Study: NCT05061979
Drug: BAY1747846
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous (IV) injection, single dose
Study: NCT04798222
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.
Study: NCT04798222
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.
Study: NCT06171776
Drug: RetroMTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium silicate lining material work as dentin substitute
Study: NCT06171776
Drug: TheraCal
Normalized name: TheraCal D2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium silicat material light cured
Study: NCT04798222
Drug: Treatment G
Normalized name: VanaLice Lice Killing Treatment Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.
Study: NCT04798222
Drug: Treatment H
Normalized name: Walgreens Lice Treatment Homeopathic Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral dose of dapagliflozin capsule in fasted condition.
Study: NCT04859751
Drug: VB4-845 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical administration of VB4-845 Injection.
Study: NCT06038279
Drug: INI-2004
Approvals — FDA: no, EMA: no, PMDA: no
Description: INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.
Study: NCT06038279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.
Study: NCT06090955
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drugs(normal saline) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
Study: NCT05626179
Drug: [14C] IBI351
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral formulation of \[14C\] IBI351 was formulated as a suspension for subjects to take orally in drinking water under fasting conditions
Study: NCT04798209
Drug: Placebo (SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-777991 matching placebo administered as hard capsules for oral use.
Study: NCT04798209
Drug: Placebo (MAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered as hard capsules for oral use, once daily.
Study: NCT05600361
Drug: hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization (DNP) magnetic resonance spectroscopy
Normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
Study: NCT04972188
Drug: ZYIL1 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLRP3 inflammasome inhibitor
Study: NCT04798209
Drug: Microtracer matching placebo (SAD - Absolute Bioavailability)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
Study: NCT05246878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match EDP-235, oral administration
Study: NCT05895123
Drug: Rosuvastatin 20 mg
Normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive one tablet rosuvastatin 20 mg every night
Study: NCT04798209
Drug: Microtracer matching placebo (MAD - ADME)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
Study: NCT06633562
Drug: Nezavist SDD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated as a spray dried dispersion (SDD) suspended in a flavored diluent.
Study: NCT04734860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent solution
Study: NCT05468645
Drug: [14C]Hemay005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Name: \[14C\]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.
Study: NCT06469190
Drug: KN5501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy.
Study: NCT06633562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated in a diluent that matches the Nezavist SDD suspension in appearance.
Study: NCT06632990
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine, oral, 100mg administered before study drug and after study drug
Study: NCT06632613
Drug: ENN0403 capsules, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules will be orally administered once a day for 5 consecutive days at low dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
Study: NCT06632613
Drug: ENN0403 capsules, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules will be orally administered once a day for 5 consecutive days at high dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the placebo capsules will be administrated through a nasogastric tube/oral gastric tube.
Study: NCT06184685
Drug: Diclofenac Microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
Study: NCT05891483
Drug: SHR-1905 Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1905 Placebo Injection
Study: NCT06071442
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive oral coated tablets of Rosuvastatin.
Study: NCT06071442
Drug: Levonorgestrel / Ethinyl Estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral tablets of Levonorgestrel/ Ethinyl Estradiol.
Study: NCT05230511
Drug: Lactobacillus RhamnosusGG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
Study: NCT05814718
Drug: modified BEAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
Study: NCT04566484
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is the placebo
Study: NCT06069830
Drug: 4 cycles of ESA regimen with sandwiched radiotherapy
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
Study: NCT06076668
Drug: Melatonin 3 MG
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive oral melatonin tablet 3 mg 9:00 p.m.
Study: NCT03851627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Arm
Study: NCT05706207
Drug: HB0030 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study: NCT05706207
Drug: HB0030 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study: NCT05706207
Drug: HB0030 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study: NCT05706207
Drug: HB0030 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study: NCT05706207
Drug: HB0030 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study: NCT05706207
Drug: HB0030 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study: NCT05706207
Drug: HB0030 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study: NCT05706207
Drug: HB0030 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study: NCT05324592
Drug: 9MW0813
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~One dose(2mg) of the drug will be injected intravitreously.
Study: NCT05519111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo equivalent
Study: NCT06005558
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml 0.9% Nacl over 20 minutes, followed by continuous infusion of normal saline for 72 hours.
Study: NCT05551793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: SC injections of equivalent volume
Study: NCT04982705
Drug: [Part 1.1] IDG-16177
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Part 1.1\] Subjects will receive a single oral dose of IMP. Dose strenght for each cohort (Cohort 1-5) is planned as 0.5, 1, 2, 5, 10mg, respectively.
Study: NCT04982705
Drug: [Part 1.1] Placebo of IDG-16177
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Part 1.1\] subjects will receive a single oral dose of IMP.
Study: NCT04982705
Drug: [Part1.2] IDG-16177
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Part 1.2\] Administration once daily for 14 days; Dose strenght for each cohort (Cohort 6-8) is planned as ≤ 2, ≤ 4, ≤ 8mg, respectively.
Study: NCT04982705
Drug: [Part 2] IDG-16177
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Part 2\] Administration once daily for 4 weeks.
Study: NCT04982705
Drug: [Part 1.2] Placebo of IDG-16177
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Part 1.2\] Administration once daily for 14 days.
Study: NCT04982705
Drug: [Part 2] Placebo of IDG-16177
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Part 2\] Administration once daily for 4 weeks.
Study: NCT05340530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a placebo.
Study: NCT04939415
Drug: mQFPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
Study: NCT04514731
Drug: Isotonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline group receives the same volume of isotonic saline, administered according to the same methods as in the magnesium group.
Study: NCT04524221
Drug: PTG-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTG-100, 600mg taken twice daily in capsule form for 42 days
Study: NCT04524221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken twice daily in capsule form for 42 days
Study: NCT04893512
Drug: Orally Suspension of CoV2-OGEN1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug
Study: NCT06554561
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 4-6 cycles will be prescribed.
Study: NCT05093296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)
Study: NCT05921591
Drug: IRL201104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilised powder for reconstitution for IV dosing
Study: NCT05921591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for IRL201104
Study: NCT06110429
Drug: Lactate, Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isovolemic and osmotic infusion Comparison of osmotic agent
Study: NCT05985798
Drug: Sin-Bev-TACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) are administered at 3-7 days after the first TACE. The study treatment of sintilimab and bevacizumab will last up to 24 months. TACE can be repeated on demand.
Study: NCT06110429
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isovolemic and osmotic infusion Comparison of osmotic agent
Study: NCT05498181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05976568
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
Study: NCT06381661
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50mg (in children: 1-2 mg/kg) IV Q6 for 7 days
Study: NCT06381661
Drug: Hydrocortisone and fludrocortisone
Normalized name: fludrocortisone and antiinfectives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 50mg IV Q6 for 7 days + Fludrocortisone 50mg orally or via gastric tube once a day for 7 days.
Study: NCT06381661
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapeutic unfractionated heparin (UFH) starting at 400 (in children: 20 IU/kg/h) IU/kg/24h (target between 0.3 and 0.5 IU/ml), adapted to the therapeutic Partial Thromboplastin Time targeting values in the range of 60 to 100 seconds, with lower intensity dosing in the range of 60 to 80 seconds, for 7 days (or ICU discharge, pending which will occur first).
Study: NCT06381661
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: 175 (in children 100 U/kg) IU/kg/24h, for 7 days (or hospital discharge pending which will occur first).
Study: NCT06381661
Drug: Recombinant humanThrombomodulin( rhTM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human thrombomodulin (rhTM) 0.06 mg/kg/j IV, for 7 days (or ICU discharge, pending which will occur first).
Study: NCT04545424
Drug: Neuromuscular Blocking Agents
Normalized name: NEUROMUSCULAR BLOCKING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
Study: NCT05842746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (with the same appearance and flavor with Elemene) of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
Study: NCT05490316
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06151652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05937386
Drug: AGMB-129
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06005012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04887194
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BCRP probe substrate